Pharma channel feed

Pfiz­er clos­es sites in New Jer­sey, North Car­oli­na as it ex­e­cutes plan for $3.5B in cost cuts

Last year
Manufacturing

Boehringer In­gel­heim pledges ‘Life for­ward’ with new cor­po­rate brand­ing

Last year
Marketing

Sen­ate De­moc­rats urge Biden ad­min­is­tra­tion to re­quire in­sur­ers to cov­er OTC birth con­trol

Last year
FDA+

No­var­tis strikes a $103M deal for blue­bird's PRV — if it wins one

Last year
FDA+

New PBM coali­tion launch­es a Wash­ing­ton, DC-tar­get­ed ad cam­paign to push for leg­isla­tive re­forms

Last year
Marketing

Deal flow in­flux: Abing­worth's new $356M fund will help Big Phar­ma ex­pand drug la­bels

Last year
Financing
Deals

An­oth­er Eylea threat: Roche ex­pands la­bel for block­buster eye drug Vabysmo

Last year
FDA+

Eu­ro­pean reg­u­la­tor says ev­i­dence shows no thy­roid can­cer link to GLP-1s

Last year
FDA+

Ab­b­Vie, Genen­tech and GSK lead new phar­ma TV brand ad­ver­tis­ing in Q3 — re­port

Last year
Marketing

CMS to kick off Medicare drug price ne­go­ti­a­tion lis­ten­ing ses­sions next week

Last year
FDA+

Ac­cen­ture boosts life sci­ences mar­ket­ing in $245M deal for No­vo Nordisk's obe­si­ty ad agency Con­cen­tri­cLife

Last year
Deals
Marketing

As Hu­mi­ra sales fall, Ab­b­Vie fo­cus­es on Skyrizi, Rin­voq growth, eyes ex­ter­nal com­bo strate­gies 

Last year

Sanofi shakes up clin­i­cal plans for trio of pro­grams from De­nali, Prin­cip­ia and Kymab deals

Last year
R&D

San­thera’s va­morolone bags FDA ap­proval for Duchenne af­ter long jour­ney

Last year

Eli Lil­ly’s ul­cer­a­tive col­i­tis drug ap­proved by FDA in crowd­ed mar­ket

Last year
FDA+

Sanofi will spin out con­sumer unit, putting weight be­hind R&D ef­forts: ‘I have to in­vest in the sci­ence now’

Last year
R&D

Study: On­col­o­gists who take phar­ma mon­ey are more like­ly to pro­vide low-val­ue treat­ments

Last year
FDA+

Law­mak­ers push for faster, con­di­tion­al FDA ap­proval path­way for rare dis­ease drugs

Last year
FDA+

UK reg­u­la­tors warn against fake Ozem­pic and Sax­en­da pens

Last year
FDA+

J&J’s first pso­ri­a­sis study ex­clu­sive to pa­tients of col­or opens door to new mar­ket­ing com­mu­ni­ca­tions

Last year
Marketing

2sev­en­ty bio stock drops 24% as com­pe­ti­tion catch­es up with BMS-part­nered mul­ti­ple myelo­ma drug

Last year

No­var­tis sues Take­da af­ter for­mer em­ploy­ee al­leged­ly shared trade se­crets

Last year
Law

Mer­ck’s Keytru­da sales eclipse $18B on the year, while num­bers for Lagevrio sur­prise

Last year
R&D

Bris­tol My­ers push­es back ‘peak’ for new prod­uct sales, cit­ing chal­leng­ing up­take for So­tyk­tu, Camzyos

Last year
R&D
First page Previous page 93949596979899 Next page Last page
A service from the Financial Times